Preliminary results of Pharma-2020 program were presented to the public

| By | Drug Manufacturing, Import Substitution, VED Drugs

Victor Dmitriev, the General Director of Association of Russian Pharmaceutical Manufacturers (ARPM), announced the preliminary results of Pharma-2020 program at the 8th Siberian Medical and Pharmaceutical Forum, which has ended in Krasnoyarsk.

“In 8 months of 2017, the retail prices for medicinal products included on the List of Vital and Essential Drugs (VED) declined by 0.9%. The prices for domestically manufactured VED decreased by 1.5%, while those for the drugs manufactured abroad declined by 0.4%. The decrease of retail prices for VED in the price range “up to 50 rubles” was 1.4%; in the price range “from 50 rubles to 500 rubles,” 0.8%; and in the price range “above 500 rubles,” 0.4%. The average rise of prices for the drugs not included in the VED List was 8.9%. This figure was 3.7% in the price range “up to 50 rubles”; 9.4% in the price range “from 50 rubles to 500 rubles”; and 9% in the price range “above 500 rubles,” said the Mr. Dmitriev.

In September 2017, the volume of commercial drug market was 59.6 billion rubles; this year, the sales rose by 7.6% compared to September 2016. The average price of a package of medicine in the commercial market of Russia was 146.4 rubles in September 2017. This was 0.7% less than in September 2016.

The implementation of Pharma-2020 program and the import substitution policy allowed the Russian medicinal products to significantly strengthen their market position. As a result, in September 2017, the share of Russian-manufactured drugs in the Russian pharmaceutical market increased to 29% compared to 28% in the same period of last year. In physical terms, the share increased by 2% and reached 59% in August 2017. This figure does not include the products made by local manufacturers.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.